Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.91 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.91 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | POLQ | O75417 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008435 | 0.97 | LMNA (1.00) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL15708803 | 0.95 | LMNA (1.00) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487929 | 0.85 | LMNA (0.79) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL12379943 | 0.84 | LMNA (0.76) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL20371480 | 0.84 | LMNA (1.00) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487449 | 0.82 | LMNA (0.66) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14555832 | 0.81 | LMNA (0.64) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL12361570 | 0.80 | LMNA (0.71) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL1007311 | 0.80 | ALDH1A1 (0.97) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL15708209 | 0.80 | LMNA (0.67) | LMNATSHRNPSR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444499-B | Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof | 山东大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-116444499-A | Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof | 山东大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-2888261-B1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2888261-A2 | ANTAGONISTS OF CHEMOKINE RECEPTORS | ChemoCentryx, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014035967-A2 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | LMNA 4596/4885TSHR 1260/4885NPSR1 276/4885 |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | LMNA 4596/4885TSHR 1260/4885NPSR1 276/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | LMNA 4015/4885TSHR 134/4885NPSR1 95/4885 |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | LMNA 4596/4885TSHR 1260/4885NPSR1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.